Laboratorios SALVAT, S.A. and WraSer Pharmaceuticals, LLC Announce Exclusive License Agreement for the Commercialization of CETRAXAL(R) (ciprofloxacin otic solution) 0.2%

Published: Jul 08, 2009

BARCELONA & RIDGELAND, Miss.--(BUSINESS WIRE)--Laboratorios SALVAT, S.A. (SALVAT) announced today that it has engaged WraSer Pharmaceuticals, LLC (WraSer) to market its CETRAXAL® product in the United States via an exclusive license agreement for a period of ten years.

Back to news